Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits
Authors
Kim , Sung Hee ; Kim, Jiseon ; Jang, Ji Yun ; Noh, Hyuna ; Park, Jisun ; Jeong, Haengdueng ; Jeon, Donghun ; Uhm, Chanyang ; Oh, Heeju ; Cho, Kyungrae ; Jeon, Yoon ; On, Dain ; Yoon, Suhyeon ; Lim, Soo-Yeon ; Kim, Sol Pin ; Lee, Youn Woo ; Jang, Hui Jeong ; Park, In ho ; Oh, Jooyeon ; SEO, JUNG SEON ; Kim, Jeong Jin ; Seok, Sang-Hyuk ; Lee, Yu Jin ; Hong, Seung-Min ; An, Se-Hee ; Kim, Seo Yeon ; Kim, Young Been ; Hwang, Ji-Yeon ; Lee, Hyo-Jung ; Bin Kim, Hong ; Choi, Kang-Seuk ; Park, Jun Won ; Seo, Jun Young ; Yun, Jun-Won ; Shin, Jeon Soo ; Lee, Ho-Young ; Kim, Kyoungmi ; Lee, Daekee ; Lee, Ho ; Nam, Ki Taek ; Seong, Je Kyung
SARS-CoV-2 ; hACE2 transgenic mice ; K18-hACE2 mice model ; SFTPB-hACE2 mice model ; SCGB1A1-hACE2 mice model
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) causing coronavirus disease 2019 (COVID-19) has been a global health concern since 2019. The viral spike protein infects the host by binding to angiotensinconverting enzyme 2 (ACE2) expressed on the cell surface, which is then processed by type II transmembrane serine protease. However, ACE2 does not react to SARS-CoV-2 in inbred wild-type mice, which poses a challenge for preclinical research with animal models, necessitating a human ACE2 (hACE2)expressing transgenic mouse model. Cytokeratin 18 (K18) promoter-derived hACE2 transgenic mice [B6.Cg-Tg(K18-ACE2)2Prlmn/J] are widely used for research on SARS-CoV-1, MERS-CoV, and SARS-CoV-2. However, SARS-CoV2 infection is lethal at =105 PFU and SARS-CoV-2 target cells are limited to type1 alveolar pneumocytes in K18-hACE2 mice, making this model incompatible with infections in the human lung. Hence, we developed lung-specific SARSCoV-2 infection mouse models with surfactant protein B ( SFTPB) and secretoglobin family 1a member 1 (Scgb1a1) promoters. After inoculation of 105 PFU of SARS-CoV-2 to the K18-hACE2, SFTPB-hACE2, and SCGB1A1hACE2 models, the peak viral titer was detected at 2 days post-infection and then gradually decreased. In K18- hACE2 mice, the body temperature decreased by approximately 10 degrees C, body weight decreased by over 20%, and the survival rate was reduced. However, SFTPB-hACE2 and SCGB1A1-hACE2 mice showed minimal clinical signs after infection. The virus targeted type I pneumocytes in K18-hACE2 mice; type II pneumocytes in SFTPB-hACE2 mice; and club, goblet, and ciliated cells in SCGB1A1-hACE2 mice. A time-dependent increase in severe lung lesions was detected in K18-hACE2 mice, whereas mild lesions developed in SFTPB-hACE2 and SCGB1A1-hACE2 mice. Spleen, small intestine, and brain lesions developed in K18-hACE2 mice but not in SFTPBhACE2 and SCGB1A1-hACE2 mice. These newly developed SFTPB-hACE2 and SCGB1A1-hACE2 mice should prove useful to expand research on hACE2mediated respiratory viruses.